date,title,source
Oct-18-18,"Trovagene to Provide Update on Onvansertib Clinical Development Program on Wednesday, October 24, 2018",PR Newswire
Oct-24-18,Trovagene Announces New Patent Claim Allowances Affirming Broad Patent Portfolio Coverage of NPM1 Mutations by U.S. Patent and Trademark Office,PR Newswire
Nov-01-18,Trovagene to Present Data from Lead Clinical Program of Onvansertib in Acute Myeloid Leukemia at the 60th American Society of Hematology Annual Meeting,PR Newswire
Nov-07-18,Trovagene Announces Third Quarter 2018 Highlights and Financial Results,PR Newswire
Nov-13-18,Trovagene Announces Launch of New Company Website,PR Newswire
Nov-15-18,"Trovagene, Inc. Receives Positive Nasdaq Listing Decision",PR Newswire
Nov-19-18,"Detailed Research: Economic Perspectives on Miller Industries, P & F Industries, Schmitt Industries, Orgenesis, AMERI, and TrovaGene  What Drives Growth in Today's Competitive Landscape",GlobeNewswire
Nov-21-18,What does TrovaGene Incs (NASDAQ:TROV) Balance Sheet Tell Us About Its Future?,Simply Wall St.
Dec-03-18,New Data from Phase 1b/2 Study of Onvansertib in Combination with LDAC or Decitabine Demonstrates Response to Treatment in Relapsed/Refractory AML,PR Newswire
Dec-11-18,Trovagene (TROV) Stock: Providing New Cancer Treatment Options With Onvansertib,ACCESSWIRE
Jan-16-19,"The Daily Biotech Pulse: Revance Common Stock Offering, Adcom Catalyst For Amgen",Benzinga
